Urinary albumin excretion and the renin–angiotensin system in cardiovascular risk management

Bibliography

• VIBERTI GC, HILL RD, JARRETT RJ, ARGYROPOULOS A, MAHMUD U, KEENH: Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet (1982) 1:1430-1432.
   PubMedGoogle Scholar
• SVENDSEN PA, OXENBOLL B, CHRISTIANSEN JS: Microalbuminuria in diabetic patients-a longitudinal study. Acta Endocrinol. Suppl. (Copenh) (1981) 242:53-54.
   Google Scholar
• MOGENSEN CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N. Engl. J. Med. (1984) 310:356-360.
   PubMed Web of Science ®Google Scholar
• K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. (2002) 39:S1-S266.
   Google Scholar
• BIANCHI S, BIGAZZI R, CAMPESE VM: Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am. J. Kidney Dis. (1999) 34:973-995.
   PubMed Web of Science ®Google Scholar
• VERHAVE JC, HILLEGE HL, DE ZEEUW D, DE JONG PE: How to measure the prevalence of microalbuminuria in relation to age and gender? Am. J. Kidney Dis. (2002) 40:436-437.
   PubMedGoogle Scholar
• GANSEVOORT RT, VERHAVE JC, HILLEGE HL et al.: The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int. Suppl. (2005) S28-S35.
   Google Scholar
• DEEN WM: What determines glomerular capillary permeability? J. Clin. Invest. (2004) 114:1412-1414.
   PubMedGoogle Scholar
• BRENNER BM, HOSTETTER TH, HUMES HD: Molecular basis of proteinuria of glomerular origin. N. Engl. J. Med. (1978) 298:826-833.
   PubMed Web of Science ®Google Scholar
• BRENNER BM, BOHRER MP, BAYLIS C, DEEN WM: Determinants of glomerular permselectivity: Insights derived from observations in vivo. Kidney Int. (1977) 12:229-237.
   PubMed Web of Science ®Google Scholar
• ROWE DJ, DAWNAY A, WATTS GF: Microalbuminuria in diabetes mellitus: review and recommendations for the measurement of albumin in urine. Ann. Clin. Biochem. (1990) 27(Pt 4):297-312.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN EI, BIRN H: Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am. J. Physiol. Renal Physiol. (2001) 280:F562-F573.
   PubMed Web of Science ®Google Scholar
• ISEKI K, IKEMIYA Y, ISEKI C, TAKISHITA S: Proteinuria and the risk of developing end-stage renal disease. Kidney Int. (2003) 63:1468-1474.
   PubMed Web of Science ®Google Scholar
• VERHAVE JC, GANSEVOORT RT, HILLEGE HL, BAKKER SJ, DE ZEEUW D, DE JONG PE: An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int. Suppl. (2004) 92:S18-S21.
   Google Scholar
• DECKERT T, FELDT-RASMUSSEN B, BORCH-JOHNSEN K, JENSEN T, KOFOED-ENEVOLDSEN A: Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia (1989) 32:219-226.
   PubMed Web of Science ®Google Scholar
• JENSEN JS: Renal and systemic transvascular albumin leakage in severe atherosclerosis. Arterioscler. Thromb. Vasc. Biol. (1995) 15:1324-1329.
   PubMed Web of Science ®Google Scholar
• FESTA A, D’AGOSTINO R, HOWARD G, MYKKANEN L, TRACY RP, HAFFNER SM: Inflammation and microalbuminuria in nondiabetic and Type 2 diabetic subjects: the Insulin Resistance Atherosclerosis Study. Kidney Int. (2000) 58:1703-1710.
   PubMed Web of Science ®Google Scholar
• STEHOUWER CD, NAUTA JJ, ZELDENRUST GC, HACKENG WH, DONKER AJ, DEN OTTOLANDER GJ: Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet (1992) 340:319-323.
   PubMed Web of Science ®Google Scholar
• CLAUSEN P, JENSEN JS, JENSEN G, BORCH-JOHNSEN K, FELDT-RASMUSSEN B: Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation (2001) 103:1869-1874.
   PubMed Web of Science ®Google Scholar
• JENSEN JS, BORCH-JOHNSEN K, JENSEN G, FELDT-RASMUSSEN B: Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin. Sci. (Lond) (1995) 88:629-633.
   PubMed Web of Science ®Google Scholar
• KLAUSEN KP, SCHARLING H, JENSEN G, JENSEN JS: New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension (2005) 46:33-37.
   PubMed Web of Science ®Google Scholar
• GERSTEIN HC, MANN JF, YI Q et al.: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA (2001) 286:421-426.
   PubMed Web of Science ®Google Scholar
• HILLEGE HL, FIDLER V, DIERCKS GF et al.: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation (2002) 106:1777-1782.
   PubMed Web of Science ®Google Scholar
• BORCH-JOHNSEN K, FELDT-RASMUSSEN B, STRANDGAARD S, SCHROLL M, JENSEN JS: Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler. Thromb. Vasc. Biol. (1999) 19:1992-1997.
   PubMedGoogle Scholar
• ROMUNDSTAD S, HOLMEN J, KVENILD K, HALLAN H, ELLEKJAER H: Microalbuminuria and all-cause mortality in 2089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway. Am. J. Kidney Dis. (2003) 42:466-473.
   PubMed Web of Science ®Google Scholar
• DAMSGAARD EM, FROLAND A, JORGENSEN OD, MOGENSEN CE: Microalbuminuria as predictor of increased mortality in elderly people. BMJ (1990) 300:297-300.
   PubMed Web of Science ®Google Scholar
• JENSEN JS, FELDT-RASMUSSEN B, STRANDGAARD S, SCHROLL M, BORCH-JOHNSEN K: Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension (2000) 35:898-903.
   PubMed Web of Science ®Google Scholar
• WACHTELL K, IBSEN H, OLSEN MH et al.: Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann. Intern. Med. (2003) 139:901-906.
   PubMed Web of Science ®Google Scholar
• ASSELBERGS FW, DIERCKS GF, HILLEGE HL et al.: Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation (2004) 110:2809-2816.
   PubMed Web of Science ®Google Scholar
• IBSEN H, OLSEN MH, WACHTELL K et al.: Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension (2005) 45:198-202.
   PubMed Web of Science ®Google Scholar
• VERHAVE JC, HILLEGE HL, BURGERHOF JG, NAVIS G, DE ZEEUW D, DE JONG PE: Cardiovascular risk factors are differently associated with urinary albumin excretion in men and women. J. Am. Soc. Nephrol. (2003) 14:1330-1335.
   PubMed Web of Science ®Google Scholar
• ROSA TT, PALATINI P: Clinical value of microalbuminuria in hypertension. J. Hypertens. (2000) 18:645-654.
   PubMed Web of Science ®Google Scholar
• JENSEN JS, FELDT-RASMUSSEN B, BORCH-JOHNSEN K, CLAUSEN P, APPLEYARD M, JENSEN G: Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1254 hypertensive individuals. J. Hum. Hypertens. (1997) 11:727-732.
   PubMedGoogle Scholar
• PARVING HH, MOGENSEN CE, JENSEN HA, EVRIN PE: Increased urinary albumin-excretion rate in benign essential hypertension. Lancet (1974) 1:1190-1192.
   PubMed Web of Science ®Google Scholar
• KNIGHT EL, KRAMER HM, CURHAN GC: High-normal blood pressure and microalbuminuria. Am. J. Kidney Dis. (2003) 41:588-595.
   PubMed Web of Science ®Google Scholar
• VERDECCHIA P, REBOLDI GP: Hypertension and microalbuminuria: the new detrimental duo. Blood Press. (2004) 13:198-211.
   Google Scholar
• LEONCINI G, SACCHI G, VIAZZI F et al.: Microalbuminuria identifies overall cardiovascular risk in essential hypertension: an artificial neural network-based approach. J. Hypertens. (2002) 20:1315-1321.
   PubMed Web of Science ®Google Scholar
• BIDANI AK, GRIFFIN KA: Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension (2004) 44:595-601.
   PubMed Web of Science ®Google Scholar
• GRISK O, RETTIG R: Interactions between the sympathetic nervous system and the kidneys in arterial hypertension. Cardiovasc. Res. (2004) 61:238-246.
   PubMedGoogle Scholar
• PEDRINELLI R, PENNO G, DELL’OMO G et al.: Microalbuminuria and transcapillary albumin leakage in essential hypertension. Hypertension (1999) 34:491-495.
   PubMed Web of Science ®Google Scholar
• BOHLEN L, DE COURTEN M, WEIDMANN P: Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am. J. Hypertens. (1994) 7:84S-92S.
   PubMed Web of Science ®Google Scholar
• BAKRIS GL, FONSECA V, KATHOLI RE et al.: Differential effects of beta-blockers on albuminuria in patients with Type 2 diabetes. Hypertension (2005) 46:1309-1315.
   PubMedGoogle Scholar
• JERUMS G, ALLEN TJ, CAMPBELL DJ et al.: Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria. Diabet. Med. (2004) 21:1192-1199.
   PubMed Web of Science ®Google Scholar
• WHITE WB, DUPREZ D, ST HILLAIRE R et al.: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension (2003) 41:1021-1026.
   PubMedGoogle Scholar
• BRANTSMA AH, BAKKER SJ, DE ZEEUW D, DE JONG PE, GANSEVOORT RT: Urinary albumin excretion as a predictor of the development of hypertension in the general population. J. Am. Soc. Nephrol. (2006) 17:331-335.
   PubMed Web of Science ®Google Scholar
• MOGENSEN CE: Prediction of clinical diabetic nephropathy in IDDM patients. Alternatives to microalbuminuria? Diabetes (1990) 39:761-767.
   PubMed Web of Science ®Google Scholar
• SCHENA FP, GESUALDO L: Pathogenetic mechanisms of diabetic nephropathy. J. Am. Soc. Nephrol. (2005) 16(Suppl. 1):S30-S33.
   PubMed Web of Science ®Google Scholar
• BOHLENDER JM, FRANKE S, STEIN G, Wolf G: Advanced glycation end products and the kidney. Am. J. Physiol. Renal Physiol. (2005) 289:F645-F659.
   PubMed Web of Science ®Google Scholar
• FERRANNINI E, BUZZIGOLI G, BONADONNA R et al.: Insulin resistance in essential hypertension. N. Engl. J. Med. (1987) 317:350-357.
   PubMed Web of Science ®Google Scholar
• BIANCHI S, BIGAZZI R, VALTRIANI C et al.: Elevated serum insulin levels in patients with essential hypertension and microalbuminuria. Hypertension (1994) 23:681-687.
   PubMed Web of Science ®Google Scholar
• GRANDI AM, SANTILLO R, ZANZI P et al.: Microalbuminuria in never-treated hypertensives: lack of relationship to hyperinsulinemia and genetic predisposition to hypertension. Am. J. Hypertens. (2000) 13:353-358.
   PubMed Web of Science ®Google Scholar
• GALL MA, HOUGAARD P, BORCH-JOHNSEN K, PARVING HH: Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ (1997) 314:783-788.
   PubMed Web of Science ®Google Scholar
• RAVID M, BROSH D, RAVID-SAFRAN D, LEVY Z, RACHMANI R: Main risk factors for nephropathy in Type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Am. J. Kidney Dis. (1998) 158:998-1004.
   Google Scholar
• CHATURVEDI N, FULLER JH, TASKINEN MR: Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of Type 1 diabetes. Diabetes Care (2001) 24:2071-2077.
   Google Scholar
• CALVINO J, CALVO C, ROMERO R, GUDE F, SANCHEZ-GUISANDE D: Atherosclerosis profile and microalbuminuria in essential hypertension. Am. J. Kidney Dis. (1999) 34:996-1001.
   PubMedGoogle Scholar
• CAMPESE VM, BIANCHI S, BIGAZZI R: Association between hyperlipidemia and microalbuminuria in essential hypertension. Kidney Int. Suppl. (1999) 71:S10-S13.
   Google Scholar
• CIRILLO M, SENIGALLIESI L, LAURENZI M et al.: Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: the Gubbio Population Study. Am. J. Kidney Dis. (1998) 158:1933-1939.
   Google Scholar
• KLAHR S, SCHREINER G, ICHIKAWA I: The progression of renal disease. N. Engl. J. Med. (1988) 318:1657-1666.
   PubMed Web of Science ®Google Scholar
• TONOLO G, CICCARESE M, BRIZZI P, et al.: Reduction of albumin excretion rate in normotensive microalbuminuric Type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care (1997) 20:1891-1895.
   PubMedGoogle Scholar
• ORTH SR: Effects of smoking on systemic and intrarenal hemodynamics: influence on renal function. J..Am. Soc. Nephrol. (2004) 15(Suppl. 1):S58-S63.
   PubMed Web of Science ®Google Scholar
• HALIMI JM, PHILIPPON C, MIMRAN A: Contrasting renal effects of nicotine in smokers and non-smokers. Nephrol. Dial. Transplant. (1998) 13:940-944.
   PubMed Web of Science ®Google Scholar
• CHASE HP, GARG SK, MARSHALL G et al.: Cigarette smoking increases the risk of albuminuria among subjects with Type I diabetes. JAMA (1991) 265:614-617.
   PubMed Web of Science ®Google Scholar
• CORRADI L, ZOPPI A, TETTAMANTI F, MALAMANI G, LAZZARI P, FOGARI R: Association between smoking and micro-albuminuria in hypertensive patients with Type 2 diabetes mellitus. J. Hypertens. Suppl. (1993) 11:S190-S191.
   PubMedGoogle Scholar
• GERSTEIN HC, MANN JF, POGUE J et al.: Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care (2000) 23(Suppl. 2):B35-B39.
   Google Scholar
• PINTO-SIETSMA SJ, MULDER J, JANSSEN WM, HILLEGE HL, DE ZEEUW D, DE JONG PE: Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann. Intern. Med. (2000) 133:585-591.
   PubMedGoogle Scholar
• HILLEGE HL, JANSSEN WM, BAK AA et al.: Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J. Intern. Med. (2001) 249:519-526.
   PubMed Web of Science ®Google Scholar
• ORTH SR, RITZ E: The renal risks of smoking: an update. Curr. Opin. Nephrol. Hypertens. (2002) 11:483-488.
   PubMed Web of Science ®Google Scholar
• CLELAND SJ, REID JL: The renin–angiotensin system and the heart: a historical review. Heart (1996) 76:7-12.
   PubMedGoogle Scholar
• HARRIS P: Evolution and the cardiac patient. Cardiovasc. Res. (1983) 17:437-445.
   PubMed Web of Science ®Google Scholar
• SKEGGS LT, LENTZ KE, KAHN JR, SHUMWAY NP, WOODS KR: The amino acid sequence of hypertensin. II. J. Exp. Med. (1956) 104:193-197.
   PubMed Web of Science ®Google Scholar
• COATES D: The angiotensin converting enzyme (ACE). Int. J. Biochem. Cell Biol. (2003) 35:769-773.
   PubMed Web of Science ®Google Scholar
• STRUTHERS AD, MACDONALD TM: Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc. Res. (2004) 61:663-670.
   PubMed Web of Science ®Google Scholar
• DE GASPARO M, CATT KJ, INAGAMI T, WRIGHT JW, UNGER T: International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. (2000) 52:415-472.
   PubMedGoogle Scholar
• KAMBAYASHI Y, BARDHAN S, TAKAHASHI K et al.: Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J. Biol. Chem. (1993) 268:24543-24546.
   PubMed Web of Science ®Google Scholar
• MURPHY TJ, ALEXANDER RW, GRIENDLING KK, RUNGE MS, BERNSTEIN KE: Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature (1991) 351:233-236.
   PubMed Web of Science ®Google Scholar
• CAMPBELL DJ: Tissue renin–angiotensin system: sites of angiotensin formation. J. Cardiovasc. Pharmacol. (1987) 10(Suppl. 7):S1-S8.
   PubMed Web of Science ®Google Scholar
• DZAU VJ: Circulating versus local renin–angiotensin system in cardiovascular homeostasis. Circulation (1988) 77:I4-I13.
   PubMed Web of Science ®Google Scholar
• BADER M, PETERS J, BALTATU O, MULLER DN, LUFT FC, GANTEN D: Tissue renin–angiotensin systems: new insights from experimental animal models in hypertension research. J. Mol. Med. (2001) 79:76-102.
   PubMed Web of Science ®Google Scholar
• ZHUO JL, IMIG JD, HAMMOND TG, ORENGO S, BENES E, NAVAR LG: Ang II accumulation in rat renal endosomes during Ang II-induced hypertension: role of AT(1) receptor. Hypertension (2002) 39:116-121.
   PubMed Web of Science ®Google Scholar
• ICHIKAWI I, HARRIS RC: Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int. (1991) 40:583-596.
   PubMed Web of Science ®Google Scholar
• DZAU VJ, RE R: Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation (1994) 89:493-498.
   PubMed Web of Science ®Google Scholar
• WANG T, GIEBISCH G: Effects of angiotensin II on electrolyte transport in the early and late distal tubule in rat kidney. Am. J. Physiol. (1996) 271:F143-F149.
   PubMedGoogle Scholar
• NAVAR LG, HARRISON-BERNARD LM, IMIG JD, WANG CT, CERVENKA L, MITCHELL KD: Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. J. Am. Soc. Nephrol. (1999) 10(Suppl. 12):S266-S272.
   Google Scholar
• MONTANARI A, BIGGI A, CARRA N et al.: Endothelin-A receptors mediate renal hemodynamic effects of exogenous angiotensin II in humans. Hypertension (2003) 42:825-830.
   PubMedGoogle Scholar
• WOLF G: Angiotensin II as a mediator of tubulointerstitial injury. Nephrol. Dial. Transplant. (2000) 15(Suppl. 6):61-63.
   PubMed Web of Science ®Google Scholar
• RUIZ-ORTEGA M, RUPEREZ M, ESTEBAN V et al.: Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol. Dial. Transplant. (2006) 21:16-20.
   PubMedGoogle Scholar
• HOLLENBERG NK: Aldosterone in the development and progression of renal injury. Kidney Int. (2004) 66:1-9.
   PubMed Web of Science ®Google Scholar
• BOHRER MP, DEEN WM, ROBERTSON CR, BRENNER BM: Mechanism of angiotensin II-induced proteinuria in the rat. Am. J. Physiol (1977) 233:F13-F21.
   Google Scholar
• LAPINSKI R, PERICO N, REMUZZI A, SANGALLI F, BENIGNI A, REMUZZI G: Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J. Am. Soc. Nephrol. (1996) 7:653-660.
   PubMed Web of Science ®Google Scholar
• GOMEZ-GARRE D, LARGO R, TEJERA N, FORTES J, MANZARBEITIA F, EGIDO J: Activation of NF-kappaB in tubular epithelial cells of rats with intense proteinuria: role of angiotensin II and endothelin-1. Hypertension (2001) 37:1171-1178.
   PubMedGoogle Scholar
• LEEHEY DJ, SINGH AK, ALAVI N, SINGH R: Role of angiotensin II in diabetic nephropathy. Kidney Int. Suppl. (2000) 77:S93-S98.
   PubMed Web of Science ®Google Scholar
• SUZUKI Y, RUIZ-ORTEGA M, LORENZO O, RUPEREZ M, ESTEBAN V, EGIDO J: Inflammation and angiotensin II. Int. J. Biochem. Cell Biol. (2003) 35:881-900.
   PubMed Web of Science ®Google Scholar
• WILLIAMS B, BAKER AQ, GALLACHER B, LODWICK D: Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension (1995) 25:913-917.
   PubMed Web of Science ®Google Scholar
• BALDONCINI R, DESIDERI G, BELLINI et al.: High plasma renin activity is combined with elevated urinary albumin excretion in essential hypertensive patients. Kidney Int. (1999) 56:1499-1504.
   PubMedGoogle Scholar
• PONTREMOLI R, SOFIA A, TIROTTA A et al.: The deletion polymorphism of the angiotensin I-converting enzyme gene is associated with target organ damage in essential hypertension. J. Am. Soc. Nephrol. (1996) 7:2550-2558.
   PubMed Web of Science ®Google Scholar
• KARIO K, KANAI N, NISHIUMA S, FUJII T et al.: Hypertensive nephropathy and the gene for angiotensin-converting enzyme. Arterioscler. Thromb. Vasc. Biol. (1997) 17:252-256.
   PubMed Web of Science ®Google Scholar
• HADJADJ S, BELLOUM R, BOUHANICK B et al.: Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in Type 1 diabetes mellitus: a prospective study. J. Am. Soc. Nephrol. (2001) 12:541-549.
   PubMed Web of Science ®Google Scholar
• PONTREMOLI R, RAVERA M, VIAZZI F et al.: Genetic polymorphism of the renin–angiotensin system and organ damage in essential hypertension. Kidney Int. (2000) 57:561-569.
   PubMed Web of Science ®Google Scholar
• AMERICAN DIABETES ASSOCIATION: Standards of medical care in diabetes. Diabetes Care (2005) 28:S4-S36. Erratum in: Diabetes Care (2005) 28(4):990.
   PubMed Web of Science ®Google Scholar
• DE ZEEUW D, REMUZZI G, PARVING HH et al.: Proteinuria, a target for renoprotection in patients with Type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. (2004) 65:2309-2320.
   PubMedGoogle Scholar
• ENGEL SL, SCHAEFFER TR, WAUGH MH, RUBIN B: Effects of the nonapeptide SQ-20881 on blood pressure of rats with experimental renovascular hypertension. Proc. Soc. Exp. Biol. Med. (1973) 143:483-487.
   PubMed Web of Science ®Google Scholar
• GAVRAS H, BRUNNER HR, LARAGH H, SEALEY JE, GAVRAS I, VUKOVICH RA: An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N. Engl. J. Med. (1974) 291:817-821.
   PubMed Web of Science ®Google Scholar
• GANSEVOORT RT, SLUITER WJ, HEMMELDER MH, DE ZEEUW D, DE JONG PE: Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol. Dial. Transplant. (1995) 10:1963-1974.
   PubMed Web of Science ®Google Scholar
• ACE INHIBITORS IN DIABETIC NEPHROPATHY TRIALIST GROUP: Should all patients with Type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann. Intern. Med. (2001) 134:370-379.
   PubMed Web of Science ®Google Scholar
• LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. (1993) 329:1456-1462.
   PubMed Web of Science ®Google Scholar
• VIBERTI G, MOGENSEN CE, GROOP LC, PAULS JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA (1994) 271:275-279.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet (2000) 355:253-259.
   PubMed Web of Science ®Google Scholar
• RUGGENENTI P, FASSI A, ILIEVA AP et al.: Preventing microalbuminuria in Type 2 diabetes. N. Engl. J. Med. (2004) 351:1941-1951.
   PubMed Web of Science ®Google Scholar
• DALLA VM, POZZA G, MOSCA A et al.: Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr. Metab. (2004) 17:259-266.
   PubMedGoogle Scholar
• NO AUTHORS LISTED: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet (1997) 349:1857-1863.
   PubMed Web of Science ®Google Scholar
• RUGGENENTI P, PERNA A, BENINI R et al.: In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigator of the GISEN group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J. Am. Soc. Nephrol. (1999) 10:997-1006.
   PubMed Web of Science ®Google Scholar
• STAESSEN JA, WANG JG, THIJS L: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet (2001) 358:1305-1315.
   PubMed Web of Science ®Google Scholar
• FOX KM: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet (2003) 362:782-788.
   PubMed Web of Science ®Google Scholar
• WING LM, REID CM, RYAN P et al.: A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med. (2003) 348:583-592.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, TUZCU EM, LIBBY P et al: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA (2004) 292:2217-2225.
   PubMed Web of Science ®Google Scholar
• DAHLOF B, SEVER PS, POULTER NR et al: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet (2005) 366:895-906.
   PubMed Web of Science ®Google Scholar
• PALS DT, MASUCCI FD, SIPOS F, DENNING GS Jr: A specific competitive antagonist of the vascular action of angiotensin. II. Circ.Res. (1971) 29:664-672.
   PubMed Web of Science ®Google Scholar
• KIDNEY DISEASE OUTCOMES QUALITY INITIATIVE (K/DOQI): K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am. J. Kidney Dis. (2004) 43:S1-S290.
   PubMed Web of Science ®Google Scholar
• BURNIER M, ZANCHI A: Blockade of the renin–angiotensin–aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J. Hypertens. (2006) 24:11-25.
   PubMed Web of Science ®Google Scholar
• BERL T: Angiotensin-converting enzyme inhibitors versus AT1 receptor antagonist in cardiovascular and renal protection: the case for AT1 receptor antagonist. J. Am. Soc. Nephrol. (2004) 15(Suppl. 1):S71-S76.
   PubMed Web of Science ®Google Scholar
• LANSANG MC, STEVANOVIC R, PRICE DA, LAFFEL LM, HOLLENBERG NK: ACE and non-ACE pathways in the renal vascular response to RAS interruption in Type 1 diabetes mellitus. Kidney Int. (2005) 67:1033-1037.
   PubMedGoogle Scholar
• BUTER H, NAVIS G, DULLAART RP, DE ZEEUW D, DE JONG PE: Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. Nephrol. Dial. Transplant. (2001) 16:771-775.
   PubMed Web of Science ®Google Scholar
• PARVING HH, LEHNERT H, BROCHNER-MORTENSEN J, GOMIS R, ANDERSEN S, ARNER P: The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N. Engl. J. Med. (2001) 345:870-878.
   PubMed Web of Science ®Google Scholar
• LEWIS EJ, HUNSICKER LG, CLARKE WR et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. (2001) 345:851-860.
   PubMed Web of Science ®Google Scholar
• BRENNER BM, COOPER ME, DE ZEEUW D et al.: Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. (2001) 345:861-869.
   PubMed Web of Science ®Google Scholar
• VIBERTI G, WHEELDON NM: Microalbuminuria reduction with valsartan in patients with Type 2 diabetes mellitus: a blood pressure-independent effect. Circulation (2002) 106:672-678.
   PubMed Web of Science ®Google Scholar
• BARNETT AH, BAIN SC, BOUTER P et al.: Angiotensin-receptor blockade versus converting-enzyme inhibition in Type 2 diabetes and nephropathy. N. Engl. J. Med. (2004) 351:1952-1961.
   PubMed Web of Science ®Google Scholar
• ZIAI F, OTS M, PROVOOST AP et al.: The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure. Kidney Int. Suppl. (1996) 57:S132-S136.
   Google Scholar
• NAKAYA H, SASAMURA H, KITAMURA Y et al.: Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis. Hypertens. Res. (1999) 22:303-312.
   PubMed Web of Science ®Google Scholar
• PLUM J, BUNTEN B, NEMETH R, GRABENSEE B: Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J. Am. Soc. Nephrol. (1998) 9:2223-2234.
   PubMed Web of Science ®Google Scholar
• GANSEVOORT RT, DE ZEEUW D, DE JONG PE: Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin–angiotensin system? Kidney Int. (1994) 45:861-867.
   PubMed Web of Science ®Google Scholar
• CHAN JC, CRITCHLEY JA, TOMLINSON B, CHAN TY, COCKRAM CS: Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am. J. Nephrol. (1997) 17:72-80.
   PubMed Web of Science ®Google Scholar
• NIELSEN S, DOLLERUP J, NIELSEN B, JENSEN HA, MOGENSEN CE: Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol. Dial. Transplant. (1997) 12(Suppl. 2):19-23.
   PubMed Web of Science ®Google Scholar
• HOLDAAS H, HARTMANN A, BERG KJ, LUND K, FAUCHALD P: Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrol.Dial.Transplant. (1998) 13:3096-3102.
   PubMed Web of Science ®Google Scholar
• HERMIDA RC, CALVO C, AYALA DE, LOPEZ JE: Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension (2005) 46:960-968.
   Google Scholar
• ISHIMITSU T, KOBAYASHI T, HONDA T et al.: Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients. Hypertens. Res. (2005) 28:351-359.
   PubMed Web of Science ®Google Scholar
• VOGT L, NAVIS G, KOSTER J, MANOLIS AJ, REID JL, DE ZEEUW D: The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. J. Hypertens. (2005) 23:2055-2061.
   PubMed Web of Science ®Google Scholar
• SONG JH, CHA SH, LEE HJ et al.: Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in Type 2 diabetic patients with advanced kidney disease. Nephrol. Dial. Transplant. (2006) 21:683-689.
   PubMed Web of Science ®Google Scholar
• FUJISAWA T, IKEGAMI H, ONO M et al.: Combination of half doses of angiotensin Type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy. Am. J. Hypertens. (2005) 18:13-17.
   PubMed Web of Science ®Google Scholar
• IBSEN H, WACHTELL K, OLSEN MH et al.: Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J. Hypertens. (2004) 22:1805-1811.
   PubMed Web of Science ®Google Scholar
• BENSON SC, PERSHADSINGH HA, HO CI et al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension (2004) 43:993-1002.
   PubMed Web of Science ®Google Scholar
• FLISER D, BUCHHOLZ K, HALLER H: Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation (2004) 110:1103-1107.
   PubMed Web of Science ®Google Scholar
• EUROPEAN SOCIETY OF HYPERTENSION-EUROPEAN SOCIETY OF CARDIOLOGY GUIDELINES COMMITTEE: 2003 EUROPEAN SOCIETY Of HYPERTENSION-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. (2003) 21:1011-1053.
   PubMedGoogle Scholar
• GREENE EL, KREN S, HOSTETTER TH: Role of aldosterone in the remnant kidney model in the rat. J. Clin. Invest. (1996) 98:1063-1068.
   PubMed Web of Science ®Google Scholar
• QUAN ZY, WALSER M, HILL GS: Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int. (1992) 41:326-333.
   PubMedGoogle Scholar
• ROCHA R, STIER CT Jr, KIFOR I et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology (2000) 141:3871-3878.
   PubMed Web of Science ®Google Scholar
• HORIUCHI M, NISHIYAMA H, HAMA J et al.: Characterization of renal aldosterone receptors in genetically hypertensive rats. Am. J. Physiol. (1993) 264:F286-F291.
   Google Scholar
• CONN JW, KNOPF RF, NESBIT RM: Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am. J. Surg. (1964) 107:159-172.
   PubMed Web of Science ®Google Scholar
• CHRYSOSTOMOU A, BECKER G: Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N. Engl. J. Med. (2001) 345:925-926.
   PubMed Web of Science ®Google Scholar
• SATO A, HAYASHI K, NARUSE M, SARUTA T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension (2003) 41:64-68.
   PubMed Web of Science ®Google Scholar
• ROSSING K, SCHJOEDT KJ, SMIDT UM, BOOMSMA F, PARVING HH: Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care (2005) 28:2106-2112.
   PubMed Web of Science ®Google Scholar
• HAYASHI M, TSUTAMOTO T, WADA A et al.: Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation (2003) 107:2559-2565.
   PubMed Web of Science ®Google Scholar
• PITT B, ZANNAD F, REMME WJ et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. (1999) 341:709-717.
   PubMed Web of Science ®Google Scholar
• MACDONALD JE, KENNEDY N, STRUTHERS AD: Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart (2004) 90:765-770.
   PubMed Web of Science ®Google Scholar
• EPSTEIN M: Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol. Dial. Transplant. (2003) 18:1984-1992.
   PubMedGoogle Scholar
• WHITE WB, DUPREZ D, ST HILLAIRE R et al.: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension (2003) 41:1021-1026.
   PubMed Web of Science ®Google Scholar
• BROWN NJ: Eplerenone: cardiovascular protection. Circulation (2003) 107:2512-2518.
   PubMed Web of Science ®Google Scholar
• PITT B, REMME W, ZANNAD F et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (2003) 348:1309-1321.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI N, YOSHIDA K, NAKANO S et al.: Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension (2006) 47:671-679.
   PubMed Web of Science ®Google Scholar
• WOOD JM, MAIBAUM J, RAHUEL J et al.: Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun. (2003) 308:698-705.
   PubMed Web of Science ®Google Scholar
• STANTON A, JENSEN C, NUSSBERGER J, O’BRIEN E: Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension (2003) 42:1137-1143.
   PubMed Web of Science ®Google Scholar
• GRADMAN AH, SCHMIEDER RE, LINS RL, NUSSBERGER J, CHIANG Y, BEDIGIAN MP: Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation (2005) 111:1012-1018.
   PubMed Web of Science ®Google Scholar
• NUSSBERGER J, WUERZNER G, JENSEN C, BRUNNER HR: Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP-100): comparison with enalapril. Hypertension (2002) 39:E1-E8.
   PubMedGoogle Scholar
• AZIZI M, MENARD J, BISSERY A et al.: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J. Am. Soc. Nephrol. (2004) 15:3126-3133.
   PubMed Web of Science ®Google Scholar
• PILZ B, SHAGDARSUREN E, WELLNER M et al.: Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension (2005) 46:569-576.
   PubMed Web of Science ®Google Scholar
• FISHER ND, HOLLENBERG NK: Renin inhibition: what are the therapeutic opportunities? J. Am. Soc. Nephrol. (2005) 16:592-599.
   PubMedGoogle Scholar
• ATTHOBARI J, ASSELBERGS FW, BOERSMA C et al.: Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: a pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clin. Ther. (2006) 28:432-444.
   PubMed Web of Science ®Google Scholar
• ROSSING K, SCHJOEDT KJ, JENSEN BR, BOOMSMA F, PARVING HH: Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with Type 2 diabetes and microalbuminuria. Kidney Int. (2005) 68:1190-1198.
   PubMed Web of Science ®Google Scholar
• MOGENSEN CE, NELDAM S, TIKKANEN I et al.: Randomised controlled trial of dual blockade of renin–angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ (2000) 321:1440-1444.
   PubMed Web of Science ®Google Scholar
• NAKAO N, YOSHIMURA A, MORITA H, TAKADA M, KAYANO T, IDEURA T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet (2003) 361:117-124.
   PubMed Web of Science ®Google Scholar